How China became the new world leader in clinical trials

BMJ 2026

View at publisher
Authors: F. A. Murphy
DOI: 10.1136/bmj.s221
Cited by: 4
References: 4

Abstract

After investing decades and billions of yuan in becoming a scientific superpower, China is well placed to benefit from the plight of the US medical research sector. But geopolitical ructions and local idiosyncrasies could complicate this, writes Flynn Murphy

Fields of Study & Subjects

Biotechnology and Related Fields Science Research and Medicine Biomedical Ethics and Regulation

Publication details

Journal / source
BMJ
Publisher
BMJ
Volume
392
Pages
s221–s221
Publication date
13 February 2026
Language
EN